Opendata, web and dolomites


Targeting the transcriptional landscape in infant AML

Total Cost €


EC-Contrib. €






 iAML-lncTARGET project word cloud

Explore the words cloud of the iAML-lncTARGET project. It provides you a very rough idea of what is the project "iAML-lncTARGET" about.

preclinical    leukemia    atlas    cell    shapes    incorporated    inherited    create    unrecognized    toxicities    basis    enormous    cancer    understand    prevalence    discovery    rna    predict    programs    achilles    dismal    arising    interventions    biobank    vulnerable    myeloid    patient    wastelands    transformation    therapeutic    hematopoietic    therapy    expertise    synergize    presumed    genome    paradigm    sustaining    expression    stage    establishing    fertile    transcriptome    heel    highlighting    susceptibility    aml    diagnosis    diversity    prognosis    renders    innovative    standards    maintaining    background    centered    infant    resolve    protein    otherwise    previously    transcriptomic    developmental    xenografts    progression    permissive    interactome    probe    treatment    oncogene    overcome    acute    shift    itself    breakthroughs    unfavorable    oncogenes    despite    origin    inducing    edit    drive    rnas    adult    coding    reflect    aberrant    stem    oncogenic    chromatin    transcriptional    obstacles    hypothesize    fetal    landscape    cells   

Project "iAML-lncTARGET" data sheet

The following table provides information about the project.


Organization address
city: HALLE (Saale)
postcode: 6108

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙750 €
 EC max contribution 1˙499˙750 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2022-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Infant acute myeloid leukemia (AML) has a dismal prognosis, with a high prevalence of unfavorable features and increased susceptibility to therapy-related toxicities, highlighting the need for innovative treatment approaches. Despite the discovery of an enormous number and diversity of transcriptional products arising from the previously presumed wastelands of the non-protein-coding genome, our knowledge of non-coding RNAs is far from being incorporated into standards of AML diagnosis and treatment. I hypothesize that the highly developmental stage- and cell-specific expression of long non-coding RNAs shapes a chromatin and transcriptional landscape in fetal hematopoietic stem cells that renders them permissive towards transformation. I predict this landscape to synergize with particular oncogenes that are otherwise not oncogenic in adult cells, by providing a fertile transcriptional background for establishing and maintaining oncogenic programs. Therefore, the non-coding transcriptome, inherited from the fetal cell of origin, may reflect a previously unrecognized Achilles heel of infant AML, which I will identify with my expertise to understand and edit the AML genome and transcriptome. I will apply recent breakthroughs from various research areas to i) create a comprehensive transcriptomic atlas of infant AML and fetal stem cells, ii) define aberrant or fetal stage-specific non-coding RNAs that drive leukemia progression, and iii) resolve their features to probe the oncogenic interactome. After iv) establishing a biobank of patient-derived xenografts, I will v) evaluate preclinical RNA-centered therapeutic interventions to overcome current obstacles in the treatment of infant AML. Targeting the vulnerable fetal stage-specific background of infant AML inherited from the cell of origin may set a paradigm shift for cancer treatment, by focusing on the permissive basis required by the oncogene for inducing and sustaining cancer, rather than on the oncogene itself.


year authors and title journal last update
List of publications.
2019 Michelle Ng, Dirk Heckl, Jan-Henning Klusmann
The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2019.00570
Frontiers in Oncology 9 2020-01-30
2019 Michaela Kuhlen, Jan-Henning Klusmann, Jessica I. Hoell
Molecular Approaches to Treating Pediatric Leukemias
published pages: , ISSN: 2296-2360, DOI: 10.3389/fped.2019.00368
Frontiers in Pediatrics 7 2020-01-30
2019 Sina Al-Kershi, Raj Bhayadia, Michelle Ng, Lonneke Verboon, Stephan Emmrich, Lucie Gack, Adrian Schwarzer, Till Strowig, Dirk Heckl, Jan-Henning Klusmann
The stem cell–specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia
published pages: 4252-4263, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2019032029
Blood Advances 3/24 2020-01-30
2020 Sarah Grasedieck, Christoph Ruess, Kathrin Krowiorz, Susanne Lux, Nicole Pochert, Adrian Schwarzer, Jan-Henning Klusmann, Mojca Jongen-Lavrencic, Tobias Herold, Lars Bullinger, Jonathan R. Pollack, Arefeh Rouhi, Florian Kuchenbauer
The long non-coding RNA Cancer Susceptibility 15 is induced by Isocitrate Dehydrogenase mutations and maintains an immature phenotype in adult acute myeloid leukemia
published pages: haematol.2019.23, ISSN: 0390-6078, DOI: 10.3324/haematol.2019.235291
Haematologica 2020-01-30
2017 Maurice Labuhn, Felix F Adams, Michelle Ng, Sabine Knoess, Axel Schambach, Emmanuelle M Charpentier, Adrian Schwarzer, Juan L Mateo, Jan-Henning Klusmann, Dirk Heckl
Refined sgRNA efficacy prediction improves large- and small-scale CRISPR–Cas9 applications
published pages: 1375-1385, ISSN: 0305-1048, DOI: 10.1093/nar/gkx1268
Nucleic Acids Research 46/3 2019-09-02
2018 Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie de Haas, Vincent H. J. van der Velden, Christine von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, Jan-Henning Klusmann
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
published pages: 1532-1540, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2018018945
Blood Advances 2/13 2019-09-02
2018 Mareike Rasche, Martin Zimmermann, Lisa Borschel, Jean-Pierre Bourquin, Michael Dworzak, Thomas Klingebiel, Thomas Lehrnbecher, Ursula Creutzig, Jan-Henning Klusmann, Dirk Reinhardt
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
published pages: 2167-2177, ISSN: 0887-6924, DOI: 10.1038/s41375-018-0071-7
Leukemia 32/10 2019-09-02
2018 Raj Bhayadia, Kathrin Krowiorz, Nadine Haetscher, Razan Jammal, Stephan Emmrich, Askar Obulkasim, Jan Fiedler, Adrian Schwarzer, Arefeh Rouhi, Michael Heuser, Susanne Wingert, Sabrina Bothur, Konstanze Döhner, Tobias Mätzig, Michelle Ng, Dirk Reinhardt, Hartmut Döhner, C. Michel Zwaan, Marry van den Heuvel Eibrink, Dirk Heckl, Maarten Fornerod, Thomas Thum, R. Keith Humphries, Michael A. Rieger, Florian Kuchenbauer, Jan-Henning Klusmann
Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia
published pages: 1007-1016, ISSN: 0732-183X, DOI: 10.1200/JCO.2017.75.2204
Journal of Clinical Oncology 36/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IAML-LNCTARGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IAML-LNCTARGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More